REDWOOD CITY, Calif., Oct. 29, 2025 /PRNewswire/ -- Codexis, Inc. (CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, and Nitto Denko Avecia, Inc.
Most of today's biological and biomedical laboratories simply could not function without ready access to user-specified oligonucleotides. Many researchers rely on core services or external vendors for ...
- The next frontier in oligonucleotide synthesis is the direct synthesis of gene-length sequences. - Ansa synthesized a 1005 base long oligonucleotide with industry-leading accuracy. - Ansa will be ...
RNA-based medicines are transforming the way we treat disease—offering targeted, precision therapies for conditions ranging from rare genetic disorders to widespread chronic illnesses like diabetes, ...
The "Oligonucleotide Synthesis Market Industry Trends and Global Forecasts to 2035: By Application Area, Type of Product Synthesized, Type of Oligonucleotide Synthesized, Scale of Operation, ...
Utilizing Vapourtec’s R-Series flow chemistry system to undertake their research, the Novo Nordisk team have made the data available in an application note that will be of interest to all chemists ...
Scientists at Novo Nordisk in Denmark have applied flow chemistry to enhance the cleavage of oligonucleotides. Utilizing Vapourtec's R-Series flow chemistry system to undertake their research, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback